Results 31 to 40 of about 13,861,407 (312)
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
Hepatology International, 2015 Worldwide, some 240 million people have chronic hepatitis B virus (HBV), with the highest rates of infection in Africa and Asia. Our understanding of the natural history of HBV infection and the potential for therapy of the resultant disease is ...S. Sarin, M. Kumar, G. Lau, Z. Abbas, H. Chan, Chien-Jen Chen, Ding‐Shinn Chen, Huey‐Ling Chen, Pei‐Jer Chen, R. Chien, A. Dokmeci, E. Gane, J. Hou, W. Jafri, J. Jia, Ju ng-Hyun Kim, Ching. Lai, Hon-Cheung Lee, S. Lim, Chun-Jen Liu, S. Locarnini, M. Mahtab, R. Mohamed, Masao Omata, J. Y. Park, T. Piratvisuth, B. Sharma, J. Sollano, F. Wang, Lai Wei, Man-Fung Yuen, Shusen Zheng, J. Kao +32 moresemanticscholar +1 more sourceBoosting Diverse Communities Participation in Clinical Trials: What People Living with Hepatitis B Must Know [PDF]
BioSocial Health JournalIntroduction: Globally, people from African, Asian and Western Pacific regions are disproportionately affected by hepatitis B virus (HBV) and are underrepresented in HBV clinical trials (trials).Yasmin Ibrahim, Tanya Machado, Fiona Borondy-Jenkins, Shreya Koirala, Mi Dong, Ibrahima Sankare, Mohamed Ali, Dung Hua, Ashley Che, Chari Cohen +9 moredoaj +1 more sourceManagement of acute hepatitis B and reactivation of hepatitis B [PDF]
Liver International, 2013 AbstractThe natural course of hepatitis B virus infection and the resulting hepatic injury is determined by the degree of virus replication and the intensity of host immune response. Upon exposure to hepatitis B virus (HBV), individuals with a vigorous and broad immune response develop acute self‐limited infection, which may result in acute hepatitis ...Ankur, Jindal, Manoj, Kumar, Shiv K, Sarin +2 moreopenaire +2 more sourcesGlobal prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study.
The Lancet Gastroenterology and Hepatology, 2018 BACKGROUND
The 69th World Health Assembly approved the Global Health Sector Strategy to eliminate viral hepatitis by 2030. Although no virological cure exists for hepatitis B virus (HBV) infection, existing therapies to control viral replication and ...D. Razavi-Shearer, I. Gamkrelidze, M. Nguyen, Ding‐Shinn Chen, P. Damme, Z. Abbas, Maheeba Abdulla, A. Rached, D. Adda, I. Aho, U. Akarca, F. Hasan, Faryal Al Lawati, K. A. Naamani, H. Al-Ashgar, S. Alavian, S. Alawadhi, A. Albillos, Said A. Al-Busafi, S. Aleman, F. Alfaleh, A. Aljumah, A. Anand, N. T. Anh, J. Arends, P. Arkkila, K. Athanasakis, A. Bane, Z. Ben‐Ari, T. Berg, A. Bizri, S. Blach, C. Mello, S. Brandon, B. Bright, P. Bruggmann, M. Brunetto, M. Buti, H. Chan, A. Chaudhry, R. Chien, M. Choi, P. Christensen, W. Chuang, V. Chulanov, M. Clausen, M. Colombo, M. Cornberg, B. Cowie, A. Craxì, E. Croes, D. Cuellar, C. Cunningham, H. Desalegn, S. Dražilová, Ann-Sofi Duberg, Steve S Egeonu, M. El-Sayed, C. Estes, K. Falconer, M. L. Ferraz, P. Ferreira, R. Flisiak, S. Fraňková, G. Gaeta, J. García-Samaniego, J. Genov, J. Gerstoft, A. Goldiş, I. Gountas, R. Gray, M. Pessoa, B. Hajarizadeh, A. Hatzakis, C. Hézode, S. Himatt, A. Hoepelman, I. Hrstic, Y. Hui, P. Husa, R. Jahis, N. Janjua, P. Jarčuška, J. Jaroszewicz, S. Kaymakoğlu, D. Kershenobich, L. Kondili, A. Konysbekova, M. Krajden, P. Kristian, W. Laleman, W. Lao, J. Layden, J. Lazarus, Mei‐Hsuan Lee, V. Liakina, Y. Lim, C. Loo, B. Lukšić, R. Malekzadeh, A. Malu, A. Mamatkulov, M. Manns, R. Marinho, M. Maticic, S. Mauss, M. Memon, M. Correa, N. Méndez-Sánchez, S. Merat, Ammal M. Metwally, R. Mohamed, J. Mokhbat, Christophe Moreno, J. Mossong, F. Mourad, B. Müllhaupt, K. Murphy, E. Musabaev, A. Nawaz, H. Nde, F. Negro, A. Nersesov, V. T. Nguyen, R. Njouom, R. Ntagirabiri, Z. Nurmatov, S. Obekpa, P. Ocama, S. Oguche, O. Omede, C. Omuemu, O. Opare-Sem, C. Opio, N. Örmeci, G. Papatheodoridis, K. Pasini, N. Pimenov, H. Poustchi, T. D. Quang, H. Qureshi, A. Ramji, K. Razavi-Shearer, B. Redae, H. Reesink, C. Ríos, G. Rjašková, S. Robbins, L. Roberts, S. Roberts, S. Ryder, R. Safadi, O. Sagalova, R. Salupere, F. Sanai, J. Sánchez-Ávila, V. Saraswat, C. Sarrazin, J. Schmelzer, I. Schréter, Julia E. Scott, C. Seguin-Devaux, Samir R. Shah, A. Sharara, Manik Sharma, G. Shiha, Tesia Shin, W. Sievert, J. Sperl, P. Stärkel, C. Stedman, V. Sypsa, F. Tacke, S. Tan, J. Tanaka, K. Tomasiewicz, P. Urbánek, A. J. Meer, H. Vlierberghe, S. Vella, A. Vince, Yasir Waheed, I. Waked, N. Walsh, N. Weis, V. Wong, J. Woodring, C. Yaghi, Hwai I. Yang, C. Yang, K. Yesmembetov, A. Yosry, M. Yuen, M. Yusuf, S. Zeuzem, H. Razavi +195 moresemanticscholar +1 more sourceIFITM3 Interacts with the HBV/HDV Receptor NTCP and Modulates Virus Entry and Infection
Viruses, 2022 The Na+/taurocholate co-transporting polypeptide (NTCP, gene symbol SLC10A1) is both a physiological bile acid transporter and the high-affinity hepatic receptor for the hepatitis B and D viruses (HBV/HDV).Massimo Palatini, Simon Franz Müller, Michael Kirstgen, Silke Leiting, Felix Lehmann, Lena Soppa, Nora Goldmann, Christin Müller, Kira Alessandra Alicia Theresa Lowjaga, Jörg Alber, Giuliano Ciarimboli, John Ziebuhr, Dieter Glebe, Joachim Geyer +13 moredoaj +1 more sourceDual-targeting nanoparticle vaccine elicits a therapeutic antibody response against chronic hepatitis B
Nature Nanotechnology, 2020 Chronic hepatitis B is caused by prolonged infection with the hepatitis B virus (HBV), which can substantially increase the risk of developing liver disease.Wenjun Wang, Xiaoxiao Zhou, Yingjie Bian, Shan Wang, Qian Chai, Zhenqian Guo, Zhenni Wang, P. Zhu, Hua Peng, Xiyun Yan, Wenhui Li, yang-xin fu, Mingzhao Zhu +12 moresemanticscholar +1 more sourceUpdate of the statements on biology and clinical impact of occult hepatitis b virus infection.
Journal of Hepatology, 2019 In October 2018 a large number of international experts with complementary expertise came together in Taormina to participate in a workshop on occult hepatitis B virus infection (OBI).G. Raimondo, S. Locarnini, T. Pollicino, M. Levrero, F. Zoulim, A. Lok, J. Allain, T. Berg, A. Bertoletti, M. Brunetto, R. Bruno, Ding‐Shinn Chen, N. Coppola, M. Cornberg, A. Craxì, M. Dandri, V. Di Marco, Carlo Ferrari, G. Gaeta, D. Glebe, L. Guidotti, A. Kramvis, P. Lampertico, Chengyao Li, Jake T. Liang, A. Marzano, T. Michalak, J. Pawlotsky, D. Prati, M. Puoti, D. Samuel, V. Soriano, G. Squadrito, C. Sureau, C. Trépo, M. Yuen +35 moresemanticscholar +1 more sourceHepatitis B vaccine development and implementation
Human Vaccines & Immunotherapeutics, 2020 Vaccination against hepatitis B is the most effective strategy to control HBV infection. The first licensed hepatitis B vaccine was developed by the purification of hepatitis B surface antigen (HBsAg) from plasma of asymptomatic HBsAg carriers. Then, the Hong Zhao, Xiaoying Zhou, Yihua Zhousemanticscholar +1 more sourceEfficacy of Birth Dose Vaccination in Preventing Mother-to-Child Transmission of Hepatitis B: A Randomized Controlled Trial Comparing Engerix-B and Sci-B-Vac
Vaccines, 2021 Background and aims: Peripartum transmission of hepatitis B virus (HBV) from an infected mother to the child can be prevented in most but not all cases by immediate vaccination of the newborn.Rifaat Safadi, Tawfik Khoury, Nizar Saed, Marwan Hakim, Jeryes Jamalia, Yousef Nijim, Nicola Farah, Tawfik Nuser, Nidaa Natur, Mahmud Mahamid, Johnny Amer, Pia L. Roppert, Wolfram H. Gerlich, Dieter Glebe +13 moredoaj +1 more source
